SCHEMBL343678

SCHEMBL343678

CC(C)(C)OC(=O)C[C@H](NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.55
CTSK P43235 7/20 0.49
CTSS P25774 6/20 0.49
PPARA Q07869 6/20 0.47
PPARG P37231 5/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
ACE P12821 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
PPARD Q03181 2/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
IDO1 P14902 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343679 1.00 CYP2D6 (0.55) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL3682214 1.00 CYP2D6 (0.55) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL344762 0.91 CTSK (0.48) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL2018992 0.91 CTSK (0.48) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL344763 0.91 CTSK (0.48) CYP2D6CTSKCTSSPPARAPPARG
Hydrochloric Acid SCHEMBL25223717 0.90 CTSK (0.47) CYP2D6CTSKCTSSPPARAPPARG
Hydrochloric Acid SCHEMBL25223716 0.90 CTSK (0.47) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL1486220 0.87 CTSS (0.50) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL3323682 0.87 CTSS (0.50) CYP2D6CTSKCTSSPPARAPPARG
SCHEMBL688341 0.87 CTSS (0.50) CYP2D6CTSKCTSSPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010782-A Gelagliptin intermediate Process for the preparation of bulk compounds 四川定科制药有限公司 2026-05-12 CN claimed
CN-119708129-A Polypeptide fluorescent probe capable of specifically detecting enterokinase and preparation method and application thereof 南京工业大学 2025-03-28 CN claimed
CN-119684406-A Enzyme response self-assembled polypeptide prodrug loaded with camptothecine, preparation and application thereof 东南大学 2025-03-25 CN claimed
CN-119119168-A Synthesis method of tyrosine sulfonated polypeptide growth factor 杭州东恒生物医药有限公司 2024-12-13 CN claimed
CN-118812626-A Method for rapid natural chemical ligation reaction of sulfhydryl aspartic acid 中国医学科学院药物研究所 2024-10-22 CN claimed
CN-117682981-A Preparation method of gemagliptin prodrug 中国科学院大连化学物理研究所 2024-03-12 CN claimed
CN-115651070-A Interchain disulfide Cys A24 -Cys B23 H2Relaxin derivatives substituted with thioether bond 合肥工业大学 2023-01-31 CN claimed
CN-112480122-B Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof 中山大学 2022-03-22 CN claimed
CN-104593173-A Detergent for grapes YANTAI SHUNLONG CHEMICAL TECHNOLOGY CO LTD 2015-05-06 CN claimed
CN-122010782-A Gelagliptin intermediate Process for the preparation of bulk compounds 四川定科制药有限公司 2026-05-12 CN disclosed
CN-122010782-A Gelagliptin intermediate Process for the preparation of bulk compounds 四川定科制药有限公司 2026-05-12 CN disclosed
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS LLC (US) 2026-03-12 US disclosed
US-20260028371-A1 HIGH PERFORMANCE AND ENVIRONMENTALLY COMPATIBLE FILMS, FIBERS, AND MEMBRANES WITH BUNDLEMER BUILDING BLOCKS UNIV DELAWARE (US) 2026-01-29 US disclosed
US-5538988-A CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS SYNTEX (U.S.A.) INC. 1996-07-23 US disclosed
WO-1995029165-A2 BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-11-02 WO disclosed
EP-0204826-A4 HEAT STABILIZED PEPTIDE SWEETENERS. JOYCE PATRICK JOSEPH 1989-02-09 EP disclosed
EP-0204826-A1 HEAT STABILIZED PEPTIDE SWEETENERS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1986-12-17 EP disclosed
WO-1986003378-A1 HEAT STABILIZED PEPTIDE SWEETENERS JOYCE PATRICK JOSEPH 1986-06-19 WO disclosed
US-3968226-A 3-Heterocyclic thiomethylcephalosporins as antibacterial agents SMITHKLINE CORPORATION (US) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, CALCB, SPPL2B CYP2D6 3211/4885CTSK 717/4885CTSS 254/4885
US-20260028371-A1 HIGH PERFORMANCE AND ENVIRONMENTALLY COMPATIBLE FILMS, FIBERS, AND MEMBRANES WITH BUNDLEMER BUILDING BLOCKS MB, BCAT2, AAAS CYP2D6 3965/4885CTSK 4630/4885CTSS 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.